Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gamida Cell Ltd. - Ordinary Shares
(NQ:
GMDA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gamida Cell Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
October 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Flotek Industries, Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying
↗
October 05, 2022
The Dow Jones jumped by more than 800 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
September 29, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Recap: Gamida Cell Q2 Earnings
↗
August 15, 2022
Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
↗
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
September 28, 2022
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.
Via
InvestorPlace
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
↗
September 28, 2022
Gainers
Via
Benzinga
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
↗
September 28, 2022
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Via
Benzinga
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
September 28, 2022
From
Gamida Cell
Via
Business Wire
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
September 28, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
September 27, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
September 19, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
September 12, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
August 15, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
August 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
August 08, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Earnings Scheduled For August 15, 2022
↗
August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Via
Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
↗
August 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 01, 2022
Via
Benzinga
FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
↗
August 01, 2022
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers...
Via
Benzinga
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
August 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
↗
July 22, 2022
During Friday's session, 61 companies made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
July 25, 2022
On Monday, 100 companies reached new 52-week lows.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
June 16, 2022
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning.
Via
InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
↗
June 16, 2022
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.
Via
Benzinga
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
June 13, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
June 10, 2022
From
Gamida Cell
Via
Business Wire
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
June 02, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
June 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
June 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
